Genocea's $30m Series C to fund vaccine pipeline including malaria candidate
This article was originally published in Scrip
Executive Summary
Next-generation vaccine developer Genocea Biosciences has raised $30 million in a Series C venture capital round that included an investment by the Bill & Melinda Gates Foundation to advance the Cambridge, Massachusetts-based company's early-stage malaria programme.